Polysilicon Company Daqo Misses Q2 Estimates, Solar Industry Challenges Weigh On Earnings
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Aug 26 2024
0mins
Should l Buy DQ?
Source: Benzinga
Financial Performance: Daqo New Energy Corp. reported a significant decline in second-quarter revenue to $219.9 million, missing estimates, and recorded an adjusted loss per ADS of $1.50, leading to a gross loss of $159.2 million.
Market Outlook: The company anticipates continued challenges in the solar industry due to oversupply and low prices, adjusting its production forecasts for the third quarter and full year while initiating a $100 million share repurchase program.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy DQ?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on DQ
Wall Street analysts forecast DQ stock price to rise
2 Analyst Rating
1 Buy
0 Hold
1 Sell
Hold
Current: 25.170
Low
18.13
Averages
28.07
High
38.00
Current: 25.170
Low
18.13
Averages
28.07
High
38.00
About DQ
Daqo New Energy Corp is a holding company primarily engaged in the manufacturing of polysilicon. The Company utilizes the chemical vapor deposition process, or the modified Siemens process, to produce polysilicon. The Company manufactures and sells polysilicon to photovoltaic product manufacturers, whereby the polysilicon is processed into ingots, wafers, cells and modules for solar power solutions. The Company offers ready-to-use polysilicon, packaged to meet crucible stacking, pulling and solidification needs. The Company also offers wafers through its downstream photovoltaic product manufacturing business. The Company mainly conducts its businesses within domestic market.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Daqo New Energy Schedules Q4 2025 Earnings Release
- Earnings Release Schedule: Daqo New Energy plans to release its unaudited financial results for the fiscal year 2025 before U.S. markets open on February 26, 2026, demonstrating the company's commitment to transparency and aiming to bolster investor confidence.
- Conference Call Timing: The company has scheduled a conference call for 8:00 AM U.S. Eastern Time on February 26, 2026, which is expected to attract analysts and investors, further enhancing market focus on its performance.
- Dial-in Information: The dial-in details for the conference call have been provided, including U.S. and international numbers, ensuring global investors can easily participate, reflecting the company's emphasis on its international investor base.
- Replay Availability: A replay of the call will be available one hour after the conclusion of the conference, through March 5, 2026, enhancing information accessibility and allowing investors who could not attend live to stay informed about company developments.
See More
Wall Street Analysts Adjust Ratings
- Analyst Rating Changes: Top Wall Street analysts have adjusted their ratings on several companies, reflecting varying market perspectives that could influence investor decisions and market trends.
- Overview of Updates: The rating changes include upgrades, downgrades, and new initiations, showcasing analysts' keen responses to market dynamics, which may lead to short-term volatility in the affected stocks.
- Investor Considerations: Investors considering purchasing VERX stock should pay attention to the latest insights from analysts to make more informed investment decisions, especially amid increasing market uncertainties.
- Market Impact Analysis: The adjustments in analysts' ratings not only affect the performance of individual stocks but may also influence overall market sentiment, prompting investors to closely monitor these changes to seize investment opportunities.
See More
Daqo New Energy Estimates 2025 Net Loss of RMB 1.0-1.3 Billion
- Net Loss Estimate: Daqo's subsidiary Xinjiang Daqo estimates a net loss of RMB 1.0 to 1.3 billion for FY2025, an improvement from the RMB 2.7 billion loss in FY2024, indicating gradual recovery amidst challenges.
- Shareholder Impact: The estimated net loss will directly affect approximately 72.8% of Daqo's equity interest in Xinjiang Daqo, highlighting ongoing concerns regarding the potential threat to the company's overall financial health despite the reduction in losses.
- Financial Reporting Discrepancy: Xinjiang Daqo's financial results are prepared under PRC GAAP, while Daqo's consolidated results are reported under U.S. GAAP, which may lead to investor misunderstandings regarding the company's overall financial condition.
- Investor Caution: The company advises investors to exercise caution regarding the preliminary loss estimate, as actual results may vary significantly from this estimate, underscoring the uncertainty and risks surrounding future financial performance.
See More
Daqo New Energy Estimates 2025 Net Loss of RMB 1.3 Billion
- Net Loss Estimate: Daqo's subsidiary Xinjiang Daqo estimates a net loss of RMB 1.0 to 1.3 billion for FY2025, an improvement from the RMB 2.7 billion loss in FY2024, indicating gradual recovery amidst challenges.
- Equity Structure: Daqo New Energy owns approximately 72.8% of Xinjiang Daqo, highlighting the close relationship between its financial performance and that of its subsidiary, suggesting future profitability will be influenced by Xinjiang Daqo's results.
- Financial Reporting Differences: The loss estimate is prepared under PRC GAAP, while Daqo's consolidated results are reported under U.S. GAAP, illustrating the differences in financial transparency and reporting standards between the two.
- Investor Caution: The company advises investors to exercise caution regarding the preliminary loss estimate, as actual results may vary significantly, emphasizing the uncertainty and risks surrounding future financial performance.
See More
Applied Optoelectronics Shares Drop 15.5%, Semiconductor Sector Declines 1.8%
- Market Underperformance: On Thursday, semiconductor stocks collectively fell by approximately 1.8%, with Applied Optoelectronics experiencing a significant drop of 15.5%, indicating pressure on the sector that could undermine investor confidence.
- Key Contributors to Decline: DAQO New Energy's shares also declined by about 10.2%, exacerbating the overall weakness in the semiconductor sector and reflecting market concerns regarding future growth prospects in this industry.
- Industry Trend Warning: The downturn in the semiconductor sector may signal a broader market correction, prompting investors to closely monitor the financial health of related companies and shifts in market demand to adjust their investment strategies accordingly.
- Investor Sentiment Fluctuation: Heightened negative sentiment towards the semiconductor industry could lead to short-term capital outflows, impacting the stock performance and financing capabilities of affected companies.
See More
The Insider Report: Get Ready for the Upcoming Buying Opportunity During the Next Market Dip
Market Overview: The stock market is experiencing turbulence, with the Nasdaq down 2.74% and a notable rotation into healthcare, which is currently the only sector showing strong opportunities. The crypto market is facing significant challenges, indicating a critical juncture ahead.
Dianthus Therapeutics: Dianthus Therapeutics (DNTH) is a clinical-stage biotech company focused on innovative therapies for autoimmune diseases, showing potential for a 95% return. Despite a high Price-to-Sales ratio, recent technical patterns suggest an upward momentum.
Daqo New Energy: Daqo New Energy (DQ), a leading polysilicon manufacturer for solar products, presents a 78% return potential. The company is well-positioned to benefit from the growing renewable energy sector, with strong operational resilience and strategic expansion plans.
Arcus Biosciences: Arcus Biosciences (RCUS) is developing advanced cancer therapies, with a 45% return potential. The company is backed by significant partnerships and funding, allowing it to aggressively pursue its pipeline while navigating the biotech landscape.
See More
Daqo New Energy Schedules Q4 2025 Earnings Release
- Earnings Release Schedule: Daqo New Energy plans to release its unaudited financial results for the fiscal year 2025 before U.S. markets open on February 26, 2026, demonstrating the company's commitment to transparency and aiming to bolster investor confidence.
- Conference Call Timing: The company has scheduled a conference call for 8:00 AM U.S. Eastern Time on February 26, 2026, which is expected to attract analysts and investors, further enhancing market focus on its performance.
- Dial-in Information: The dial-in details for the conference call have been provided, including U.S. and international numbers, ensuring global investors can easily participate, reflecting the company's emphasis on its international investor base.
- Replay Availability: A replay of the call will be available one hour after the conclusion of the conference, through March 5, 2026, enhancing information accessibility and allowing investors who could not attend live to stay informed about company developments.
See More
Wall Street Analysts Adjust Ratings
- Analyst Rating Changes: Top Wall Street analysts have adjusted their ratings on several companies, reflecting varying market perspectives that could influence investor decisions and market trends.
- Overview of Updates: The rating changes include upgrades, downgrades, and new initiations, showcasing analysts' keen responses to market dynamics, which may lead to short-term volatility in the affected stocks.
- Investor Considerations: Investors considering purchasing VERX stock should pay attention to the latest insights from analysts to make more informed investment decisions, especially amid increasing market uncertainties.
- Market Impact Analysis: The adjustments in analysts' ratings not only affect the performance of individual stocks but may also influence overall market sentiment, prompting investors to closely monitor these changes to seize investment opportunities.
See More
Daqo New Energy Estimates 2025 Net Loss of RMB 1.0-1.3 Billion
- Net Loss Estimate: Daqo's subsidiary Xinjiang Daqo estimates a net loss of RMB 1.0 to 1.3 billion for FY2025, an improvement from the RMB 2.7 billion loss in FY2024, indicating gradual recovery amidst challenges.
- Shareholder Impact: The estimated net loss will directly affect approximately 72.8% of Daqo's equity interest in Xinjiang Daqo, highlighting ongoing concerns regarding the potential threat to the company's overall financial health despite the reduction in losses.
- Financial Reporting Discrepancy: Xinjiang Daqo's financial results are prepared under PRC GAAP, while Daqo's consolidated results are reported under U.S. GAAP, which may lead to investor misunderstandings regarding the company's overall financial condition.
- Investor Caution: The company advises investors to exercise caution regarding the preliminary loss estimate, as actual results may vary significantly from this estimate, underscoring the uncertainty and risks surrounding future financial performance.
See More
Daqo New Energy Estimates 2025 Net Loss of RMB 1.3 Billion
- Net Loss Estimate: Daqo's subsidiary Xinjiang Daqo estimates a net loss of RMB 1.0 to 1.3 billion for FY2025, an improvement from the RMB 2.7 billion loss in FY2024, indicating gradual recovery amidst challenges.
- Equity Structure: Daqo New Energy owns approximately 72.8% of Xinjiang Daqo, highlighting the close relationship between its financial performance and that of its subsidiary, suggesting future profitability will be influenced by Xinjiang Daqo's results.
- Financial Reporting Differences: The loss estimate is prepared under PRC GAAP, while Daqo's consolidated results are reported under U.S. GAAP, illustrating the differences in financial transparency and reporting standards between the two.
- Investor Caution: The company advises investors to exercise caution regarding the preliminary loss estimate, as actual results may vary significantly, emphasizing the uncertainty and risks surrounding future financial performance.
See More
Applied Optoelectronics Shares Drop 15.5%, Semiconductor Sector Declines 1.8%
- Market Underperformance: On Thursday, semiconductor stocks collectively fell by approximately 1.8%, with Applied Optoelectronics experiencing a significant drop of 15.5%, indicating pressure on the sector that could undermine investor confidence.
- Key Contributors to Decline: DAQO New Energy's shares also declined by about 10.2%, exacerbating the overall weakness in the semiconductor sector and reflecting market concerns regarding future growth prospects in this industry.
- Industry Trend Warning: The downturn in the semiconductor sector may signal a broader market correction, prompting investors to closely monitor the financial health of related companies and shifts in market demand to adjust their investment strategies accordingly.
- Investor Sentiment Fluctuation: Heightened negative sentiment towards the semiconductor industry could lead to short-term capital outflows, impacting the stock performance and financing capabilities of affected companies.
See More
The Insider Report: Get Ready for the Upcoming Buying Opportunity During the Next Market Dip
Market Overview: The stock market is experiencing turbulence, with the Nasdaq down 2.74% and a notable rotation into healthcare, which is currently the only sector showing strong opportunities. The crypto market is facing significant challenges, indicating a critical juncture ahead.
Dianthus Therapeutics: Dianthus Therapeutics (DNTH) is a clinical-stage biotech company focused on innovative therapies for autoimmune diseases, showing potential for a 95% return. Despite a high Price-to-Sales ratio, recent technical patterns suggest an upward momentum.
Daqo New Energy: Daqo New Energy (DQ), a leading polysilicon manufacturer for solar products, presents a 78% return potential. The company is well-positioned to benefit from the growing renewable energy sector, with strong operational resilience and strategic expansion plans.
Arcus Biosciences: Arcus Biosciences (RCUS) is developing advanced cancer therapies, with a 45% return potential. The company is backed by significant partnerships and funding, allowing it to aggressively pursue its pipeline while navigating the biotech landscape.
See More
